Karolinska Development Relationship 'No Longer Exclusive'
This article was originally published in Clinica
Karolinska Development AB and Karolinska Institutet Holding AB (the technology transfer company of the Karolinska Institute) have renegotiated their relationship into a new non-exclusive deal flow agreement. The new terms will give the Karolinska Institute access to a broader range of funding sources and allow it to build stronger links with industry partners.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.